QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
See you at Ispor!
ISPOREurope is fast approaching, and the Quantify Research team is looking forward to meeting with our current and future collaborators as well as presenting a wide variety of research.
Quantify will have a large group of in-house experts with diverse experience and expertise on-site to discuss your needs and our solutions – Don’t hesitate to schedule a meeting with us in advance. We are keen to talk with you about:
✔️ ?????? […]
Did you know Quantify is an ENcePP partner conducting PASS Studies?
Since 2020, Quantify Research has been a proud partner to the European Medicines Agency coordinated ENCePP (European NEtwork for Centers of Pharmacoepidemiology and Pharmacovigilance) initiative.
This network brings together expertise and resources in pharmacoepidemiology and pharmacovigilance across Europe with the aim of conducting high quality, multi-center, independent Post Authorization Safety Studies (PASS) with a focus on observational research.
Quantify Research has executed a variety of imposed- and […]
Harnessing the power of Nordic real-world data: Quantify assesses the impact of pneumococcal conjugate vaccines (PCVs) in paediatric immunisation programmes in Denmark, Finland, Norway and Sweden!
Using 10 years of national surveillance data from four Nordic countries, Quantify Research in collaboration with Pfizer found that a substantial amount of vaccine-preventable invasive pneumococcal disease remains present in elderly populations, despite the inclusion of pneumococcal conjugate vaccines (PCVs) in paediatric national immunisation programmes. Further, the choice of PCV used in paediatric immunisation programmes was associated with differences in serotype distribution and disease incidence amongst older […]
Will patient prevalence play a larger role in TLV’s assessments?
That’s a possible conclusion to draw from Sweden’s HTA body The Dental and Pharmaceutical Benefits Agency, TLV‘s report published this week, on the topic of improving access to drugs for rare diseases.https://www.linkedin.com/company/tlv-the-dental-and-pharmaceutical-benefits-agency/
The pharmaceutical market has shifted in recent decades to a landscape where more highly specialized medicines are developed for small patient populations, with illnesses that often are severe. However, costs relating to drug development, manufacturing […]